However, the most advanced subunit malaria vaccine, RTS,S, which is based on the immunodominant circumsporozoite protein (CSP), only exhibited a 32–50% anti-disease (but not anti-infection) efficacy among African children in Phase IIIb trials [12], [13]. Here, DNAJC5 is linked to malaria.